Your AI-Trained Oncology Knowledge Connection!
Panelists discuss how trastuzumab deruxtecan (Enhertu) is used to treat HER2-positive metastatic breast cancer with brain metastases, emphasizing its effectiveness in achieving systemic tumor reduction and CNS lesion stabilization while exploring treatment challenges and emerging strategies in this patient population.
Panelists discuss how they approach the treatment of HER2-positive advanced breast cancer with brain metastases, outlining the criteria for therapy selection, the role of patient-specific factors in shaping treatment strategies, and situations where they might adjust their approach.
Panelists discuss the DESTINY-Breast12 trial, reviewing its study design, rationale, and key efficacy and safety findings in HER2-positive metastatic breast cancer patients with brain metastases, focusing on differences in outcomes between patients with active vs stable brain metastases, and the role of trastuzumab deruxtecan (T-DXd) in expanding treatment options for this patient population.
Panelists discuss how the DESTINY-Breast12 trial has influenced their approach to using trastuzumab deruxtecan (T-DXd) for patients with HER2-positive advanced breast cancer with brain metastases, highlighting the patient subgroups most likely to benefit from T-DXd and its impact on treatment sequencing for those with active brain metastases.
Panelists discuss how significant systemic metastases, particularly in patients with breast cancer (BC) with brain metastases, influence treatment decisions, focusing on how these factors can impact the approach to therapy and the management of complex cases.
Panelists discuss the management of HER2-positive breast cancer with brain relapse or progression, focusing on treatment strategies, challenges, and emerging therapies for improving outcomes in this patient population.
Panelists discuss recent data from the HER2CLIMB-02 trial, highlighting the findings and their implications for treatment practices in HER2-positive breast cancer, particularly for patients with brain metastases.
Panelists discuss the design and rationale of the ongoing BRIDGET (NCT05323955) trial, focusing on how its outcomes could potentially shape the future treatment landscape for HER2-positive breast cancer, particularly in patients with brain metastases.
Panelists discuss novel and emerging strategies for managing HER2-positive advanced breast cancer with brain metastases, highlighting recent advancements that show promise and could transform the treatment landscape for this patient population in the future.
